The Nolan X-1002 flip-up helmet is relatively expensive, louder than average and somewhat uncomfortable due to a thin liner. Two hands needed to rotate the flip-up visor. Includes an external sun ...
Capricor Therapeutics, Inc. (CAPR) has a significant catalyst that is rapidly approaching, which could change the scope of this biotech. This would be regarding the release of top-line data from ...
Capricor Therapeutics is seeking FDA approval for CAP-1002, targeting heart function in Duchenne Muscular Dystrophy (DMD) patients, with a PDUFA date in August 2025. Despite promising science, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results